About: Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Sector: Healthcare
Industry: Biotechnology
Latest price: $169.96 (+8.99%)
BLTE NASDAQ Belite Bio Inc ADR
Belite Bio Inc ADR share price
Atividade de preço de BLTE
Último preço
$ 157,540
Variação (24h)
1,60 USD (1,03%)
Volume
390
Volume (média 4 sem.)
-
Fechamento anterior
$ 155,94
Último negócio
12 Nov, 12:40 pm GMT+0
Atrasado
12 Nov, 12:40 pm GMT+0
BLTE price performance
Atrasado
12 Nov, 12:40 pm GMT+0
BLTE details
quote.marketSignals